Vigil Neuroscience, Inc. (NASDAQ:VIGL – Get Free Report) saw a large increase in short interest in November. As of November 15th, there was short interest totalling 736,700 shares, an increase of 51.3% from the October 31st total of 487,000 shares. Based on an average trading volume of 112,200 shares, the days-to-cover ratio is currently 6.6 days. Approximately 3.9% of the shares of the stock are short sold.
Vigil Neuroscience Price Performance
Shares of VIGL traded up $0.17 during trading hours on Friday, hitting $2.47. 336,264 shares of the stock were exchanged, compared to its average volume of 236,055. Vigil Neuroscience has a fifty-two week low of $2.08 and a fifty-two week high of $6.06. The business has a 50-day moving average of $3.42 and a 200-day moving average of $3.64. The firm has a market capitalization of $100.97 million, a P/E ratio of -1.16 and a beta of 1.92.
Institutional Trading of Vigil Neuroscience
Large investors have recently bought and sold shares of the business. Acadian Asset Management LLC bought a new stake in shares of Vigil Neuroscience during the 2nd quarter valued at about $26,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Vigil Neuroscience during the 2nd quarter worth approximately $87,000. Renaissance Technologies LLC increased its stake in shares of Vigil Neuroscience by 19.2% in the 2nd quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock valued at $286,000 after acquiring an additional 11,536 shares in the last quarter. Walleye Capital LLC increased its stake in shares of Vigil Neuroscience by 334.4% in the 3rd quarter. Walleye Capital LLC now owns 119,792 shares of the company’s stock valued at $407,000 after acquiring an additional 92,217 shares in the last quarter. Finally, Verition Fund Management LLC acquired a new position in shares of Vigil Neuroscience during the 3rd quarter valued at $442,000. 83.64% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
View Our Latest Analysis on VIGL
About Vigil Neuroscience
Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.
Recommended Stories
- Five stocks we like better than Vigil Neuroscience
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- What is MarketRankā¢? How to Use it
- 3 Penny Stocks Ready to Break Out in 2025
- Insider Buying Explained: What Investors Need to Know
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for Vigil Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vigil Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.